New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences' TissueCypher[R] Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett's Esophagus

Oral abstract will share data showing that TissueCypher alone, compared to combining the test's results with a patient's clinicopathologic risk factors, like age and pathology diagnosis, is the strongest predictor [...]